US FDA update on nitrosamine impurities investigation

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1739卷 / 1期

关键词：

D O I：

10.1007/s40278-019-57642-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[11] Nitrosamine Impurities in Angiotensin Receptor Blockers
Shephard, Emily A.
Nawarskas, James J.
CARDIOLOGY IN REVIEW, 2020, 28 (05) : 262 - 265
[12] REDUCTION OF NITROSAMINE IMPURITIES IN PESTICIDE FORMULATIONS
PROBST, GW
ACS SYMPOSIUM SERIES, 1981, 174 : 363 - 382
[13] Accuretic recall due to nitrosamine impurities
Reactions Weekly, 2022, 1914 (1) : 1 - 1
[14] Updated acceptable intake for nitrosamine impurities
Reactions Weekly, 2024, 2021 (1) : 5 - 5
[15] REDUCTION OF NITROSAMINE IMPURITIES IN PESTICIDE FORMULATIONS
PROBST, GW
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1981, 181 (MAR): : 68 - AGFD
[16] US FDA provides update on CardioGen-82 safety
Reactions Weekly, 2012, 1386 (1) : 4 - 4
[17] Presence of nitrosamine impurities in medicinal products
Sedlo, Ilijana
Kolonic, Teo
Tomic, Sinisa
ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2021, 72 (01): : 1 - 5
[18] Nitrosamine impurities in angiotensin receptor blockers
Reactions Weekly, 2019, 1770 (1) : 4 - 4
[19] EMA recommendations on nitrosamine impurities in sartans
Reactions Weekly, 2020, 1832 (1) : 4 - 4
[20] The EU Response to the Presence of Nitrosamine Impurities in Medicines
Ruepp, Robin
Froetschl, Roland
Bream, Robert
Filancia, Maria
Girard, Thomas
Spinei, Andrei
Weise, Martina
Whomsley, Rhys
FRONTIERS IN MEDICINE, 2021, 8

← 1 2 3 4 5 →